- Home
- JBLU vs ZLAB Comparison
JBLU vs ZLAB Comparison
Compare JBLU & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- ZLAB
- Stock Information
- Founded
- JBLU 1998
- ZLAB 2013
- Country
- JBLU United States
- ZLAB China
- Employees
- JBLU N/A
- ZLAB N/A
- Industry
- JBLU Air Freight/Delivery Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- ZLAB Health Care
- Exchange
- JBLU Nasdaq
- ZLAB Nasdaq
- Market Cap
- JBLU 2.0B
- ZLAB 1.8B
- IPO Year
- JBLU N/A
- ZLAB 2017
- Fundamental
- Price
- JBLU $5.67
- ZLAB $31.24
- Analyst Decision
- JBLU Hold
- ZLAB Strong Buy
- Analyst Count
- JBLU 10
- ZLAB 4
- Target Price
- JBLU $6.31
- ZLAB $52.50
- AVG Volume (30 Days)
- JBLU 17.0M
- ZLAB 976.3K
- Earning Date
- JBLU 10-29-2024
- ZLAB 11-12-2024
- Dividend Yield
- JBLU N/A
- ZLAB N/A
- EPS Growth
- JBLU N/A
- ZLAB N/A
- EPS
- JBLU N/A
- ZLAB N/A
- Revenue
- JBLU $9,327,000,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- JBLU N/A
- ZLAB $48.34
- Revenue Next Year
- JBLU $4.68
- ZLAB $47.12
- P/E Ratio
- JBLU N/A
- ZLAB N/A
- Revenue Growth
- JBLU N/A
- ZLAB 28.16
- 52 Week Low
- JBLU $3.42
- ZLAB $13.48
- 52 Week High
- JBLU $8.07
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- JBLU 38.78
- ZLAB 70.41
- Support Level
- JBLU $6.86
- ZLAB $31.52
- Resistance Level
- JBLU $7.49
- ZLAB $36.60
- Average True Range (ATR)
- JBLU 0.37
- ZLAB 1.36
- MACD
- JBLU -0.18
- ZLAB 0.34
- Stochastic Oscillator
- JBLU 0.46
- ZLAB 58.60
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.